707 reports of this reaction
2.4% of all RALTEGRAVIR reports
#9 most reported adverse reaction
ANHEDONIA is the #9 most commonly reported adverse reaction for RALTEGRAVIR, manufactured by Merck Sharp & Dohme LLC. There are 707 FDA adverse event reports linking RALTEGRAVIR to ANHEDONIA. This represents approximately 2.4% of all 29,953 adverse event reports for this drug.
Patients taking RALTEGRAVIR who experience anhedonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANHEDONIA is a less commonly reported adverse event for RALTEGRAVIR, but still significant enough to appear in the safety profile.
In addition to anhedonia, the following adverse reactions have been reported for RALTEGRAVIR:
The following drugs have also been linked to anhedonia in FDA adverse event reports:
ANHEDONIA has been reported as an adverse event in 707 FDA reports for RALTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANHEDONIA accounts for approximately 2.4% of all adverse event reports for RALTEGRAVIR, making it a notable side effect.
If you experience anhedonia while taking RALTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.